Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes

Использование искусственного интеллекта и машинного обучения для ускорения разработки методов лечения, изменяющих течение сахарного диабета 1-го типа
Mark Allen Clements, Todd M. Brusko, Amanda L. Posgai, Melanie R. Shapiro, Matthew E. Brown, Erin M. Tallon
2024-12-19

artificial intelligencedigital twin modelsmachine learningmulti-omics technologiestype 1 diabetes
Progress in developing therapies for the maintenance of endogenous insulin secretion in, or the prevention of, type 1 diabetes has been hindered by limited animal models, the length and cost of clinical trials, difficulties in identifying individuals who will progress faster to a clinical diagnosis of type 1 diabetes, and heterogeneous clinical responses in intervention trials. Classic placebo-controlled intervention trials often include monotherapies, broad participant populations and extended follow-up periods focused on clinical endpoints. While this approach remains the 'gold standard' of clinical research, efforts are underway to implement new approaches harnessing the power of artificial intelligence and machine learning to accelerate drug discovery and efficacy testing. Here, we review emerging approaches for repurposing agents used to treat diseases that share pathogenic pathways with type 1 diabetes and selecting synergistic combinations of drugs to maximise therapeutic efficacy. We discuss how emerging multi-omics technologies, including analysis of antigen processing and presentation to adaptive immune cells, may lead to the discovery of novel biomarkers and subsequent translation into antigen-specific immunotherapies. We also discuss the potential for using artificial intelligence to create 'digital twin' models that enable rapid in silico testing of personalised agents as well as dose determination. To conclude, we discuss some limitations of artificial intelligence and machine learning, including issues pertaining to model interpretability and bias, as well as the continued need for validation studies via confirmatory intervention trials.
1
Artificial intelligence and machine learning are being developed to accelerate discovery and efficacy testing of therapies preserving endogenous insulin secretion or preventing type 1 diabetes.
2
Artificial intelligence could generate digital twins for rapid in silico testing of personalized treatments and dose determination.
3
Computational approaches can repurpose drugs targeting pathways shared with type 1 diabetes and identify synergistic drug combinations to improve therapeutic efficacy.
4
Model interpretability and bias remain important limitations, and AI-derived findings still require validation in confirmatory intervention trials.
5
Multi-omics analyses, including antigen processing and presentation to adaptive immune cells, may reveal biomarkers enabling antigen-specific immunotherapies.

Disease-modifying therapies for type 1 diabetes aimed at preserving endogenous insulin secretion or preventing disease progression

AI- and machine-learning-enabled acceleration of therapy discovery, repurposing, synergistic drug-combination selection, biomarker identification, antigen-specific immunotherapy development, and personalised efficacy and dose testing

Publication Details
Publication Date
2024-12-19
Journal
Publisher
ISSN
Cited by
24
Access Type
Author Information
Authors
Mark Allen Clements
Todd M. Brusko
Amanda L. Posgai
Melanie R. Shapiro
Matthew E. Brown
Erin M. Tallon
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%